Cargando…

Imaging of Oligometastatic Disease

SIMPLE SUMMARY: The imaging of oligometastatic disease (OMD) is challenging as it requires precise loco-regional staging and whole-body assessment. The combination of imaging modalities is often required. The more accurate imaging tool will be selected according to tumor type, the timing with regard...

Descripción completa

Detalles Bibliográficos
Autores principales: Vietti Violi, Naik, Hajri, Rami, Haefliger, Laura, Nicod-Lalonde, Marie, Villard, Nicolas, Dromain, Clarisse
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8946296/
https://www.ncbi.nlm.nih.gov/pubmed/35326586
http://dx.doi.org/10.3390/cancers14061427
_version_ 1784674162379325440
author Vietti Violi, Naik
Hajri, Rami
Haefliger, Laura
Nicod-Lalonde, Marie
Villard, Nicolas
Dromain, Clarisse
author_facet Vietti Violi, Naik
Hajri, Rami
Haefliger, Laura
Nicod-Lalonde, Marie
Villard, Nicolas
Dromain, Clarisse
author_sort Vietti Violi, Naik
collection PubMed
description SIMPLE SUMMARY: The imaging of oligometastatic disease (OMD) is challenging as it requires precise loco-regional staging and whole-body assessment. The combination of imaging modalities is often required. The more accurate imaging tool will be selected according to tumor type, the timing with regard to measurement and treatment, metastatic location, and the patient’s individual risk for metastasis. The most commonly used modalities are contrast-enhanced computed tomography (CT), magnetic resonance imaging and metabolic and receptor-specific imaging, particularly, (18)F-fluorodesoxyglucose positron emission tomography/CT, used alone or in combination. ABSTRACT: Oligometastatic disease (OMD) is an emerging state of disease with limited metastatic tumor burden. It should be distinguished from polymetastatic disease due the potential curative therapeutic options of OMD. Imaging plays a pivotal role in the diagnosis and follow-up of patients with OMD. The imaging tools needed in the case of OMD will differ according to different parameters, which include primary tumor type, timing between measurement and treatment, potential metastatic location and the patient’s individual risk for metastasis. In this article, OMD is defined and the use of different imaging modalities in several oncologic situations are described in order to better understand OMD and its specific implication for radiologists.
format Online
Article
Text
id pubmed-8946296
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-89462962022-03-25 Imaging of Oligometastatic Disease Vietti Violi, Naik Hajri, Rami Haefliger, Laura Nicod-Lalonde, Marie Villard, Nicolas Dromain, Clarisse Cancers (Basel) Review SIMPLE SUMMARY: The imaging of oligometastatic disease (OMD) is challenging as it requires precise loco-regional staging and whole-body assessment. The combination of imaging modalities is often required. The more accurate imaging tool will be selected according to tumor type, the timing with regard to measurement and treatment, metastatic location, and the patient’s individual risk for metastasis. The most commonly used modalities are contrast-enhanced computed tomography (CT), magnetic resonance imaging and metabolic and receptor-specific imaging, particularly, (18)F-fluorodesoxyglucose positron emission tomography/CT, used alone or in combination. ABSTRACT: Oligometastatic disease (OMD) is an emerging state of disease with limited metastatic tumor burden. It should be distinguished from polymetastatic disease due the potential curative therapeutic options of OMD. Imaging plays a pivotal role in the diagnosis and follow-up of patients with OMD. The imaging tools needed in the case of OMD will differ according to different parameters, which include primary tumor type, timing between measurement and treatment, potential metastatic location and the patient’s individual risk for metastasis. In this article, OMD is defined and the use of different imaging modalities in several oncologic situations are described in order to better understand OMD and its specific implication for radiologists. MDPI 2022-03-10 /pmc/articles/PMC8946296/ /pubmed/35326586 http://dx.doi.org/10.3390/cancers14061427 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Vietti Violi, Naik
Hajri, Rami
Haefliger, Laura
Nicod-Lalonde, Marie
Villard, Nicolas
Dromain, Clarisse
Imaging of Oligometastatic Disease
title Imaging of Oligometastatic Disease
title_full Imaging of Oligometastatic Disease
title_fullStr Imaging of Oligometastatic Disease
title_full_unstemmed Imaging of Oligometastatic Disease
title_short Imaging of Oligometastatic Disease
title_sort imaging of oligometastatic disease
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8946296/
https://www.ncbi.nlm.nih.gov/pubmed/35326586
http://dx.doi.org/10.3390/cancers14061427
work_keys_str_mv AT viettiviolinaik imagingofoligometastaticdisease
AT hajrirami imagingofoligometastaticdisease
AT haefligerlaura imagingofoligometastaticdisease
AT nicodlalondemarie imagingofoligometastaticdisease
AT villardnicolas imagingofoligometastaticdisease
AT dromainclarisse imagingofoligometastaticdisease